Fosun Pharma: XH-S004 tablet initiates phase II clinical trial.

Fosun Pharma announced that its controlling subsidiary, Zhejiang Xinghaopengbo Pharmaceutical Co., Ltd., has initiated a Phase II clinical trial of XH-S004 tablets for the treatment of non-cystic fibrosis bronchiectasis. As of April 2025, another indication for XH-S004 has received clinical trial approval in China. As of the announcement date, the cumulative research and development investment in XH-S004 is approximately RMB 61 million.